BEUDAMED
    FDA PMA FDA Class 3 30-Day Notice Accepted 🇺🇸 United States

    Endovascular System For Treatment Of Thoracoabdominal And Pararenal Aortic Lesions

    PMA: P230023 · Supplement: S011 · Decision Apr 9, 2026
    View on FDA
    Classifications
    1
    FEI Numbers
    0
    Registration Numbers
    0

    Basic Information

    Device Name
    Endovascular System For Treatment Of Thoracoabdominal And Pararenal Aortic Lesions
    Trade Name
    GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE)
    PMA Number
    P230023
    Supplement Number
    S011
    Device Class
    FDA Class 3
    Product Code
    QZK
    Generic Name
    Endovascular system for treatment of thoracoabdominal and pararenal aortic lesions
    Medical Specialty
    Unknown
    Advisory Committee
    Cardiovascular
    Decision
    30-Day Notice Accepted
    Decision Code
    OK30
    Decision Date
    April 9, 2026
    Date Received
    March 12, 2026
    Supplement Type
    30-Day Notice
    Supplement Reason
    Process Change - Manufacturer/Sterilizer/Packager/Supplier
    Expedited Review
    N

    Advisory Committee Statement

    implementation of an alternative UV curing system for assembly of components of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE) delivery system

    Classifications

    This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

    Product Code Device Name
    QZK Endovascular System For Treatment Of Thoracoabdominal And Pararenal Aortic Lesions